Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.43 |
| ▸ | PI4KA | P42356 | 1/20 | 0.42 |
| ▸ | PI4K2B | Q8TCG2 | 1/20 | 0.42 |
| ▸ | PI4K2A | Q9BTU6 | 1/20 | 0.42 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.42 |
| ▸ | P2RX3 | P56373 | 3/20 | 0.42 |
| ▸ | P2RX1 | P51575 | 2/20 | 0.42 |
| ▸ | P2RX4 | Q99571 | 2/20 | 0.42 |
| ▸ | AMD1 | P17707 | 2/20 | 0.37 |
| ▸ | ADK | P55263 | 5/20 | 0.37 |
| ▸ | PRMT5 | O14744 | 3/20 | 0.35 |
| ▸ | METTL3 | Q86U44 | 2/20 | 0.35 |
| ▸ | ATG7 | O95352 | 3/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10067434 | 0.91 | RXFP1 (0.41) | RXFP1PI4KAPI4K2BPI4K2API4KB | |
| SCHEMBL10067433 | 0.89 | PI4KA (0.54) | RXFP1PI4KAPI4K2BPI4K2API4KB | |
| SCHEMBL91051 | 0.87 | ADK (0.51) | ADKPRMT5METTL3ATG7 | |
| SCHEMBL10067435 | 0.80 | PI4KA (0.51) | RXFP1PI4KAPI4K2BPI4K2API4KB | |
| SCHEMBL10067432 | 0.78 | ADK (0.48) | ADKPRMT5METTL3ATG7 | |
| SCHEMBL68465 | 0.75 | PI4KA (0.51) | RXFP1PI4KAPI4K2BPI4K2API4KB | |
| SCHEMBL12405891 | 0.75 | ADK (0.57) | PI4KAPI4K2BPI4K2API4KBADK | |
| SCHEMBL91058 | 0.75 | RXFP1 (0.46) | RXFP1PI4KAPI4K2BPI4K2API4KB | |
| SCHEMBL31526096 | 0.70 | PI4KA (0.49) | RXFP1PI4KAPI4K2BPI4K2API4KB | |
| SCHEMBL12522464 | 0.70 | ADK (0.60) | ADKPRMT5METTL3ATG7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8129106-B2 | Sequence-specific detection of methylation in biomolecules | Max-Planck-Geselischaft zur Forderung der Wissenschaften E.V. (DE) | 2012-03-06 | — | — | US | disclosed |
| US-20110165564-A1 | SEQUENCE-SPECIFIC DETECTION OF METHYLATION IN BIOMOLECULES | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 2011-07-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110165564-A1 | SEQUENCE-SPECIFIC DETECTION OF METHYLATION IN BIOMOLECULES | DNMT1, MAT2B, AHCY | RXFP1 4742/4885PI4KA 4743/4885PI4K2B 4739/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.